Ipsen (LTS:0MH6) Valuation Rank

View and export this data going back to 2010. Start your Free Trial

What is Ipsen Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Ipsen Valuation Rank Related Terms

Thank you for viewing the detailed overview of Ipsen's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Ipsen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (LTS:0MH6) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

IPSEY:USA IPSEF:USA IPNp:UK IPN:France I7G:Germany

Address

65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100

Website

https://www.ipsen.com

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.